| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 47 | 2021 | 2119 | 3.300 |
Why?
|
| Islets of Langerhans Transplantation | 24 | 2008 | 745 | 1.950 |
Why?
|
| Kidney Transplantation | 39 | 2022 | 4251 | 1.860 |
Why?
|
| Transplantation, Heterologous | 28 | 2022 | 2382 | 1.840 |
Why?
|
| Tissue and Organ Procurement | 12 | 2021 | 896 | 1.680 |
Why?
|
| Islets of Langerhans | 17 | 2005 | 1352 | 1.500 |
Why?
|
| Graft Survival | 28 | 2022 | 3737 | 1.320 |
Why?
|
| Organ Transplantation | 7 | 2023 | 1139 | 1.300 |
Why?
|
| Liver Failure | 7 | 2021 | 241 | 1.120 |
Why?
|
| Tissue Donors | 17 | 2021 | 2240 | 1.110 |
Why?
|
| Graft Rejection | 32 | 2022 | 4397 | 1.110 |
Why?
|
| Bibliometrics | 2 | 2024 | 339 | 0.890 |
Why?
|
| Brain Death | 6 | 2021 | 348 | 0.880 |
Why?
|
| Immunosuppressive Agents | 24 | 2022 | 4149 | 0.840 |
Why?
|
| Antigens, Heterophile | 5 | 2020 | 69 | 0.830 |
Why?
|
| Swine | 18 | 2022 | 5917 | 0.810 |
Why?
|
| Liver, Artificial | 1 | 2021 | 56 | 0.800 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2015 | 504 | 0.660 |
Why?
|
| Genes, bcl-2 | 6 | 2004 | 122 | 0.640 |
Why?
|
| Mycophenolic Acid | 11 | 2011 | 343 | 0.630 |
Why?
|
| Animals, Genetically Modified | 13 | 2022 | 1549 | 0.610 |
Why?
|
| Physicians, Women | 1 | 2024 | 486 | 0.610 |
Why?
|
| Tacrolimus | 7 | 2018 | 743 | 0.580 |
Why?
|
| Chemoembolization, Therapeutic | 5 | 2016 | 129 | 0.580 |
Why?
|
| Estradiol | 5 | 2005 | 2020 | 0.570 |
Why?
|
| Reperfusion Injury | 8 | 2012 | 1026 | 0.510 |
Why?
|
| Papio | 9 | 2022 | 656 | 0.490 |
Why?
|
| Living Donors | 4 | 2020 | 620 | 0.480 |
Why?
|
| Double-Balloon Enteroscopy | 1 | 2013 | 9 | 0.470 |
Why?
|
| Alabama | 12 | 2019 | 98 | 0.470 |
Why?
|
| Kidney Diseases | 4 | 2021 | 2149 | 0.470 |
Why?
|
| Diabetes Mellitus, Experimental | 11 | 2005 | 1116 | 0.450 |
Why?
|
| Antibodies, Heterophile | 5 | 2021 | 126 | 0.440 |
Why?
|
| Gene Transfer Techniques | 7 | 2004 | 1224 | 0.440 |
Why?
|
| Periodicals as Topic | 1 | 2024 | 1432 | 0.430 |
Why?
|
| Dilatation | 1 | 2013 | 291 | 0.420 |
Why?
|
| Pancreas Transplantation | 11 | 2004 | 187 | 0.400 |
Why?
|
| Patient Selection | 8 | 2021 | 4215 | 0.380 |
Why?
|
| Authorship | 2 | 2024 | 271 | 0.380 |
Why?
|
| Liver | 14 | 2020 | 7474 | 0.370 |
Why?
|
| Cholestasis | 1 | 2013 | 378 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2021 | 2214 | 0.360 |
Why?
|
| Immunoglobulin G | 8 | 2018 | 4560 | 0.350 |
Why?
|
| Waiting Lists | 6 | 2021 | 692 | 0.350 |
Why?
|
| Donor Selection | 3 | 2021 | 201 | 0.340 |
Why?
|
| Professional-Family Relations | 1 | 2013 | 482 | 0.340 |
Why?
|
| Liver Cirrhosis | 6 | 2017 | 1863 | 0.340 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2019 | 1366 | 0.330 |
Why?
|
| Adenoviridae | 8 | 2007 | 1099 | 0.330 |
Why?
|
| Specialization | 1 | 2013 | 777 | 0.320 |
Why?
|
| Organ Preservation | 7 | 2002 | 331 | 0.310 |
Why?
|
| Inflammation Mediators | 5 | 2003 | 1889 | 0.300 |
Why?
|
| Liver Diseases | 5 | 2021 | 1253 | 0.290 |
Why?
|
| Liver Neoplasms | 11 | 2021 | 4253 | 0.280 |
Why?
|
| End Stage Liver Disease | 2 | 2021 | 314 | 0.270 |
Why?
|
| Kidney | 12 | 2022 | 7186 | 0.270 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 1836 | 0.260 |
Why?
|
| Physicians | 1 | 2024 | 4567 | 0.260 |
Why?
|
| Cytokines | 10 | 2010 | 7322 | 0.250 |
Why?
|
| Hepatitis C | 4 | 2018 | 1591 | 0.240 |
Why?
|
| Protein C | 1 | 2004 | 138 | 0.240 |
Why?
|
| Animals | 62 | 2022 | 168757 | 0.240 |
Why?
|
| Glomerulonephritis | 1 | 2006 | 372 | 0.240 |
Why?
|
| Monkey Diseases | 1 | 2004 | 77 | 0.230 |
Why?
|
| Social Class | 1 | 2012 | 1999 | 0.230 |
Why?
|
| Histocompatibility | 3 | 2021 | 330 | 0.220 |
Why?
|
| Polylysine | 1 | 2003 | 133 | 0.220 |
Why?
|
| Haplorhini | 1 | 2004 | 552 | 0.220 |
Why?
|
| Gene Knockout Techniques | 4 | 2020 | 809 | 0.220 |
Why?
|
| Male | 82 | 2024 | 350118 | 0.220 |
Why?
|
| Survival Analysis | 12 | 2021 | 10252 | 0.220 |
Why?
|
| Immunotoxins | 8 | 2003 | 179 | 0.220 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2018 | 1475 | 0.220 |
Why?
|
| Nitric Oxide | 3 | 2014 | 2132 | 0.220 |
Why?
|
| Apoptosis | 10 | 2005 | 9727 | 0.220 |
Why?
|
| Humans | 108 | 2024 | 744343 | 0.210 |
Why?
|
| Macaca mulatta | 17 | 2018 | 2375 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2005 | 1285 | 0.210 |
Why?
|
| Family | 1 | 2013 | 3147 | 0.210 |
Why?
|
| Health Services Accessibility | 6 | 2019 | 5137 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2003 | 227 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 5 | 2019 | 9274 | 0.210 |
Why?
|
| Galactosyltransferases | 3 | 2019 | 263 | 0.210 |
Why?
|
| Carbohydrates | 2 | 2021 | 394 | 0.200 |
Why?
|
| Stents | 1 | 2013 | 3280 | 0.200 |
Why?
|
| Portal Vein | 2 | 2003 | 437 | 0.200 |
Why?
|
| Hepatic Artery | 1 | 2002 | 245 | 0.190 |
Why?
|
| Ureterostomy | 1 | 2000 | 17 | 0.190 |
Why?
|
| Endoplasmic Reticulum | 2 | 2005 | 1144 | 0.190 |
Why?
|
| Cystostomy | 1 | 2000 | 26 | 0.190 |
Why?
|
| Oligopeptides | 2 | 2003 | 1189 | 0.190 |
Why?
|
| Mice, SCID | 8 | 2005 | 2716 | 0.190 |
Why?
|
| Genetic Vectors | 7 | 2007 | 3420 | 0.190 |
Why?
|
| Postoperative Complications | 12 | 2021 | 15295 | 0.180 |
Why?
|
| Insulin | 12 | 2004 | 6580 | 0.180 |
Why?
|
| Renal Insufficiency | 1 | 2006 | 804 | 0.180 |
Why?
|
| Simvastatin | 1 | 2002 | 360 | 0.180 |
Why?
|
| Chi-Square Distribution | 6 | 2016 | 3508 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 10 | 2004 | 3336 | 0.170 |
Why?
|
| Kidney Failure, Chronic | 3 | 2021 | 2538 | 0.170 |
Why?
|
| Primates | 3 | 2019 | 545 | 0.170 |
Why?
|
| Aneurysm | 1 | 2002 | 339 | 0.160 |
Why?
|
| Guanidines | 5 | 2003 | 193 | 0.160 |
Why?
|
| Cytoprotection | 3 | 2005 | 210 | 0.160 |
Why?
|
| Middle Aged | 44 | 2021 | 213383 | 0.160 |
Why?
|
| Immunoglobulin M | 2 | 2020 | 1537 | 0.160 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2017 | 5 | 0.160 |
Why?
|
| Life Support Care | 1 | 2019 | 228 | 0.150 |
Why?
|
| Retrospective Studies | 34 | 2021 | 77449 | 0.150 |
Why?
|
| Models, Animal | 3 | 2019 | 2171 | 0.150 |
Why?
|
| Female | 59 | 2024 | 380194 | 0.150 |
Why?
|
| Urinary Bladder | 5 | 1995 | 1172 | 0.150 |
Why?
|
| Caspases | 4 | 2005 | 928 | 0.150 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2017 | 65 | 0.150 |
Why?
|
| Treatment Outcome | 25 | 2021 | 63114 | 0.140 |
Why?
|
| Adult | 38 | 2021 | 214055 | 0.140 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2018 | 369 | 0.140 |
Why?
|
| Endothelium, Vascular | 3 | 2003 | 4456 | 0.140 |
Why?
|
| Mixed Function Oxygenases | 1 | 2017 | 272 | 0.130 |
Why?
|
| Transplantation Immunology | 1 | 1998 | 546 | 0.130 |
Why?
|
| Time Factors | 24 | 2021 | 40075 | 0.130 |
Why?
|
| Organ Preservation Solutions | 3 | 2003 | 98 | 0.130 |
Why?
|
| Health Care Rationing | 1 | 2018 | 437 | 0.130 |
Why?
|
| Rats, Inbred Lew | 3 | 2012 | 1162 | 0.130 |
Why?
|
| Drainage | 6 | 1995 | 1142 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 4933 | 0.130 |
Why?
|
| Drug Therapy, Combination | 9 | 2021 | 6489 | 0.130 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 3505 | 0.130 |
Why?
|
| Lung Transplantation | 3 | 2021 | 1153 | 0.130 |
Why?
|
| Risk Adjustment | 1 | 2018 | 594 | 0.130 |
Why?
|
| Cold Ischemia | 1 | 2015 | 65 | 0.120 |
Why?
|
| Sirolimus | 2 | 2021 | 1564 | 0.120 |
Why?
|
| Peritoneovenous Shunt | 1 | 1994 | 9 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 7913 | 0.120 |
Why?
|
| Lymphocele | 1 | 1994 | 16 | 0.120 |
Why?
|
| Enzyme Activation | 4 | 2005 | 3701 | 0.120 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2016 | 1209 | 0.120 |
Why?
|
| Amebiasis | 1 | 2014 | 34 | 0.120 |
Why?
|
| Bile Ducts | 1 | 2015 | 284 | 0.120 |
Why?
|
| Mice, Inbred NOD | 3 | 2003 | 1878 | 0.120 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 3158 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2018 | 764 | 0.120 |
Why?
|
| Tissue Survival | 2 | 2003 | 118 | 0.120 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2013 | 159 | 0.110 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 18029 | 0.110 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2013 | 87 | 0.110 |
Why?
|
| Arteries | 1 | 2018 | 1119 | 0.110 |
Why?
|
| Transportation | 1 | 2015 | 214 | 0.110 |
Why?
|
| Histocompatibility Testing | 4 | 2019 | 741 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2006 | 4420 | 0.110 |
Why?
|
| Sodium Nitrite | 1 | 2012 | 14 | 0.110 |
Why?
|
| Epitopes | 1 | 2019 | 2571 | 0.110 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 598 | 0.110 |
Why?
|
| Shock, Hemorrhagic | 1 | 2014 | 220 | 0.110 |
Why?
|
| Organizational Policy | 1 | 2015 | 429 | 0.110 |
Why?
|
| B-Lymphocytes | 4 | 2022 | 4665 | 0.110 |
Why?
|
| United States | 12 | 2024 | 69872 | 0.100 |
Why?
|
| Logistic Models | 4 | 2016 | 13408 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2016 | 6538 | 0.100 |
Why?
|
| Cadaver | 4 | 2003 | 1337 | 0.100 |
Why?
|
| Coronary Artery Bypass | 1 | 2001 | 2289 | 0.100 |
Why?
|
| Transplantation, Homologous | 12 | 2003 | 4776 | 0.100 |
Why?
|
| Marital Status | 1 | 2012 | 437 | 0.100 |
Why?
|
| Policy Making | 1 | 2015 | 554 | 0.090 |
Why?
|
| Mice | 20 | 2007 | 81183 | 0.090 |
Why?
|
| Immune Tolerance | 7 | 2003 | 2258 | 0.090 |
Why?
|
| Allopurinol | 4 | 2012 | 191 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2001 | 1536 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2021 | 1855 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 4554 | 0.090 |
Why?
|
| Cell Nucleus | 3 | 2003 | 2969 | 0.090 |
Why?
|
| Risk Assessment | 7 | 2021 | 23338 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 1130 | 0.090 |
Why?
|
| Sus scrofa | 2 | 2021 | 437 | 0.090 |
Why?
|
| Decision Making | 2 | 2014 | 3887 | 0.090 |
Why?
|
| Cell Death | 3 | 2007 | 1706 | 0.090 |
Why?
|
| Smad Proteins | 1 | 2010 | 162 | 0.090 |
Why?
|
| Aged | 18 | 2021 | 163280 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2010 | 225 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 1790 | 0.080 |
Why?
|
| NF-kappa B | 3 | 2010 | 2499 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2005 | 1182 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 9 | 2005 | 21827 | 0.080 |
Why?
|
| Catheterization | 2 | 2013 | 1470 | 0.080 |
Why?
|
| Muromonab-CD3 | 2 | 1999 | 96 | 0.080 |
Why?
|
| Fatty Liver | 2 | 2012 | 727 | 0.080 |
Why?
|
| Creatinine | 5 | 2004 | 1919 | 0.080 |
Why?
|
| Transplantation Tolerance | 2 | 2003 | 617 | 0.080 |
Why?
|
| Raffinose | 3 | 2003 | 52 | 0.080 |
Why?
|
| Anemia | 1 | 2017 | 1506 | 0.080 |
Why?
|
| Necrosis | 4 | 2014 | 1643 | 0.080 |
Why?
|
| Risk Factors | 13 | 2021 | 72290 | 0.080 |
Why?
|
| Caspase 12 | 2 | 2005 | 11 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2006 | 3002 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 3255 | 0.080 |
Why?
|
| Medically Uninsured | 1 | 2013 | 853 | 0.070 |
Why?
|
| Intestinal Mucosa | 2 | 2010 | 3036 | 0.070 |
Why?
|
| Gastric Mucosa | 1 | 2010 | 599 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2010 | 382 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 1998 | 275 | 0.070 |
Why?
|
| Graft vs Host Disease | 2 | 2018 | 2957 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2010 | 386 | 0.070 |
Why?
|
| Methylprednisolone | 5 | 2000 | 387 | 0.070 |
Why?
|
| T-Lymphocytes | 5 | 2018 | 10180 | 0.070 |
Why?
|
| Blood Glucose | 8 | 2005 | 6256 | 0.070 |
Why?
|
| Survival Rate | 8 | 2015 | 12788 | 0.070 |
Why?
|
| Cause of Death | 2 | 2013 | 3584 | 0.070 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 39050 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 3966 | 0.070 |
Why?
|
| Reoperation | 5 | 2015 | 4201 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 1434 | 0.060 |
Why?
|
| Phenylbutyrates | 1 | 2005 | 69 | 0.060 |
Why?
|
| Macrophages | 3 | 2010 | 5655 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 1213 | 0.060 |
Why?
|
| Glutathione | 3 | 2003 | 589 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2010 | 1057 | 0.060 |
Why?
|
| Cell Survival | 3 | 2004 | 5882 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2014 | 1329 | 0.060 |
Why?
|
| Cells, Cultured | 5 | 2018 | 19229 | 0.060 |
Why?
|
| Transplantation, Isogeneic | 1 | 2004 | 257 | 0.060 |
Why?
|
| Educational Status | 1 | 2012 | 2540 | 0.060 |
Why?
|
| Pancreas, Artificial | 1 | 2005 | 54 | 0.060 |
Why?
|
| Gene Expression | 4 | 2012 | 7799 | 0.060 |
Why?
|
| Cyclosporine | 4 | 2000 | 786 | 0.060 |
Why?
|
| Hepacivirus | 2 | 2011 | 1379 | 0.060 |
Why?
|
| Stromal Cells | 2 | 2006 | 1355 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5078 | 0.060 |
Why?
|
| Trypsinogen | 2 | 1994 | 86 | 0.060 |
Why?
|
| Caspase 8 | 1 | 2004 | 195 | 0.060 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 159 | 0.060 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2003 | 45 | 0.060 |
Why?
|
| Streptozocin | 1 | 2004 | 196 | 0.060 |
Why?
|
| Brefeldin A | 1 | 2003 | 72 | 0.060 |
Why?
|
| Calcimycin | 1 | 2003 | 222 | 0.060 |
Why?
|
| Age Factors | 5 | 2019 | 18370 | 0.060 |
Why?
|
| Income | 1 | 2012 | 1913 | 0.060 |
Why?
|
| Tunicamycin | 1 | 2003 | 112 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2006 | 690 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2011 | 1031 | 0.060 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 1420 | 0.060 |
Why?
|
| Thrombosis | 3 | 2003 | 2968 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1991 | 2015 | 0.060 |
Why?
|
| Medicaid | 1 | 2016 | 2736 | 0.050 |
Why?
|
| Urologic Diseases | 3 | 1994 | 244 | 0.050 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 128 | 0.050 |
Why?
|
| Culture Techniques | 1 | 2003 | 554 | 0.050 |
Why?
|
| Neutrophils | 3 | 2005 | 3719 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2006 | 673 | 0.050 |
Why?
|
| Biopsy | 5 | 2011 | 6756 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2012 | 2050 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2003 | 286 | 0.050 |
Why?
|
| bcl-Associated Death Protein | 1 | 2002 | 107 | 0.050 |
Why?
|
| Length of Stay | 5 | 2015 | 6309 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2002 | 188 | 0.050 |
Why?
|
| Bioethics | 1 | 2004 | 116 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 2 | 2010 | 2007 | 0.050 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 12354 | 0.050 |
Why?
|
| Adenosine | 3 | 2003 | 825 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 573 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 2003 | 1827 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2002 | 216 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 732 | 0.050 |
Why?
|
| Propensity Score | 2 | 2021 | 1781 | 0.050 |
Why?
|
| Hepatectomy | 2 | 2005 | 550 | 0.050 |
Why?
|
| Iliac Vein | 1 | 2002 | 72 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2004 | 758 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 726 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2021 | 2488 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 1 | 2003 | 317 | 0.050 |
Why?
|
| Elapid Venoms | 1 | 2021 | 40 | 0.050 |
Why?
|
| Neuraminic Acids | 1 | 2021 | 22 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2013 | 1901 | 0.050 |
Why?
|
| Quercetin | 1 | 2002 | 93 | 0.050 |
Why?
|
| Transfection | 5 | 2002 | 5892 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 452 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2006 | 810 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 5391 | 0.050 |
Why?
|
| Oncolytic Virotherapy | 1 | 2007 | 498 | 0.050 |
Why?
|
| Preoperative Care | 3 | 2005 | 2250 | 0.050 |
Why?
|
| Arginine | 1 | 2004 | 944 | 0.050 |
Why?
|
| Cercopithecidae | 1 | 2020 | 22 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 514 | 0.050 |
Why?
|
| Monocytes | 2 | 2010 | 2596 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2003 | 575 | 0.050 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2000 | 41 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2013 | 2494 | 0.050 |
Why?
|
| Hemobilia | 1 | 2000 | 20 | 0.050 |
Why?
|
| Transcription Factors | 4 | 2005 | 12208 | 0.050 |
Why?
|
| Dendritic Cells | 2 | 2010 | 2725 | 0.050 |
Why?
|
| Iliac Artery | 1 | 2002 | 364 | 0.050 |
Why?
|
| Rats | 3 | 2012 | 24260 | 0.050 |
Why?
|
| Transplantation, Heterotopic | 1 | 2000 | 175 | 0.050 |
Why?
|
| Choledochostomy | 1 | 2000 | 15 | 0.050 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2000 | 68 | 0.050 |
Why?
|
| Common Bile Duct | 1 | 2000 | 109 | 0.050 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 1999 | 20 | 0.050 |
Why?
|
| Lymphocyte Activation | 2 | 2010 | 5524 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 903 | 0.040 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2000 | 111 | 0.040 |
Why?
|
| Primate Diseases | 1 | 1999 | 15 | 0.040 |
Why?
|
| Mitochondria | 2 | 2002 | 3520 | 0.040 |
Why?
|
| Antilymphocyte Serum | 1 | 2021 | 492 | 0.040 |
Why?
|
| Cholangitis | 1 | 2000 | 108 | 0.040 |
Why?
|
| Cholecystitis | 1 | 2000 | 182 | 0.040 |
Why?
|
| Multivariate Analysis | 5 | 2014 | 12245 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2002 | 421 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2004 | 804 | 0.040 |
Why?
|
| Biliary Tract Diseases | 1 | 2000 | 161 | 0.040 |
Why?
|
| Virus Replication | 1 | 2007 | 2534 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2010 | 8436 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2014 | 6365 | 0.040 |
Why?
|
| Tissue Preservation | 1 | 1999 | 182 | 0.040 |
Why?
|
| Recovery of Function | 3 | 2003 | 2925 | 0.040 |
Why?
|
| Technetium Tc 99m Pentetate | 2 | 1995 | 68 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2001 | 795 | 0.040 |
Why?
|
| Glucose | 3 | 2002 | 4397 | 0.040 |
Why?
|
| Anastomosis, Surgical | 3 | 2015 | 987 | 0.040 |
Why?
|
| Biological Transport | 1 | 2002 | 2118 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1999 | 482 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2004 | 1538 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2007 | 1786 | 0.040 |
Why?
|
| Health Maintenance Organizations | 1 | 2000 | 642 | 0.040 |
Why?
|
| Cost Control | 1 | 2000 | 624 | 0.040 |
Why?
|
| Azathioprine | 1 | 1999 | 353 | 0.040 |
Why?
|
| Intestines | 1 | 2006 | 1924 | 0.040 |
Why?
|
| Transplants | 1 | 2019 | 209 | 0.040 |
Why?
|
| Liver Function Tests | 2 | 2014 | 528 | 0.040 |
Why?
|
| Inflammation | 3 | 2014 | 10638 | 0.040 |
Why?
|
| Diphtheria Toxin | 2 | 2000 | 255 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2006 | 11366 | 0.040 |
Why?
|
| Adolescent | 9 | 2014 | 85781 | 0.040 |
Why?
|
| Antibodies | 2 | 2022 | 2460 | 0.040 |
Why?
|
| Hemofiltration | 1 | 1996 | 57 | 0.030 |
Why?
|
| Death | 1 | 2021 | 678 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 1351 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 1998 | 355 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2000 | 8324 | 0.030 |
Why?
|
| Temperature | 1 | 2002 | 2206 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 4751 | 0.030 |
Why?
|
| Pancreatic Ducts | 1 | 1997 | 328 | 0.030 |
Why?
|
| Prothrombin Time | 1 | 1995 | 119 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 1997 | 257 | 0.030 |
Why?
|
| Hemostatics | 1 | 1998 | 229 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2002 | 3144 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2003 | 5179 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 1504 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 5867 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2000 | 694 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2002 | 1613 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2017 | 841 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 1995 | 206 | 0.030 |
Why?
|
| Platelet Transfusion | 2 | 2014 | 314 | 0.030 |
Why?
|
| Ammonia | 1 | 1995 | 239 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1998 | 389 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 6622 | 0.030 |
Why?
|
| Hirschsprung Disease | 1 | 1996 | 155 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 345 | 0.030 |
Why?
|
| Hemoglobins | 2 | 2017 | 1534 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2005 | 1880 | 0.030 |
Why?
|
| Urography | 1 | 1995 | 313 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2000 | 1050 | 0.030 |
Why?
|
| Recurrence | 3 | 2015 | 8340 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2002 | 10943 | 0.030 |
Why?
|
| Registries | 3 | 2019 | 8089 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 1995 | 418 | 0.030 |
Why?
|
| Prednisone | 1 | 1999 | 1574 | 0.030 |
Why?
|
| Antioxidants | 1 | 2002 | 1663 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2002 | 2503 | 0.030 |
Why?
|
| Bilirubin | 1 | 1995 | 425 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2014 | 1850 | 0.030 |
Why?
|
| Capsules | 1 | 2014 | 196 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2019 | 7729 | 0.030 |
Why?
|
| Glucose Tolerance Test | 3 | 2003 | 1150 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 2170 | 0.030 |
Why?
|
| Biliary Atresia | 1 | 1993 | 73 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 713 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 2 | 2014 | 565 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 7785 | 0.030 |
Why?
|
| Macaca fascicularis | 3 | 2000 | 915 | 0.030 |
Why?
|
| Urethral Diseases | 1 | 1993 | 53 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2002 | 2938 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 2886 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 610 | 0.030 |
Why?
|
| Resource Allocation | 1 | 2015 | 341 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1995 | 676 | 0.030 |
Why?
|
| Health Care Costs | 3 | 2015 | 3209 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 1995 | 865 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2002 | 1486 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2000 | 955 | 0.030 |
Why?
|
| Nitrites | 1 | 2012 | 160 | 0.030 |
Why?
|
| Minority Groups | 1 | 2019 | 1223 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 1107 | 0.030 |
Why?
|
| Drug Approval | 1 | 2018 | 742 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 1508 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1998 | 1301 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 3768 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2017 | 1381 | 0.020 |
Why?
|
| Risk | 1 | 2004 | 9687 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2014 | 9849 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2012 | 270 | 0.020 |
Why?
|
| Theophylline | 1 | 1991 | 132 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2007 | 11725 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2017 | 5974 | 0.020 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1991 | 139 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 9734 | 0.020 |
Why?
|
| Aortic Valve | 1 | 2001 | 1922 | 0.020 |
Why?
|
| Benzoates | 1 | 2012 | 217 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 968 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2003 | 2758 | 0.020 |
Why?
|
| Phytohemagglutinins | 2 | 2001 | 170 | 0.020 |
Why?
|
| Phenotype | 2 | 2018 | 16365 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2014 | 1654 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 20129 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2002 | 5021 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 1770 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2000 | 3772 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2000 | 1876 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1915 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1998 | 2107 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2006 | 21746 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2001 | 1965 | 0.020 |
Why?
|
| Child | 7 | 2015 | 77709 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 2647 | 0.020 |
Why?
|
| Alleles | 1 | 2019 | 6933 | 0.020 |
Why?
|
| Colon | 1 | 1996 | 1772 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1994 | 1241 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 15076 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 5853 | 0.020 |
Why?
|
| Organ Size | 2 | 2005 | 2252 | 0.020 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2007 | 76 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1999 | 2376 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1993 | 788 | 0.020 |
Why?
|
| Thrombelastography | 2 | 1998 | 164 | 0.020 |
Why?
|
| Cohort Studies | 4 | 2015 | 40561 | 0.020 |
Why?
|
| Cold Temperature | 2 | 2000 | 772 | 0.020 |
Why?
|
| Dogs | 4 | 1992 | 3912 | 0.020 |
Why?
|
| Hemodynamics | 2 | 2012 | 4199 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 1993 | 1173 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2001 | 6077 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1993 | 1904 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 1206 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 2002 | 1547 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 1998 | 3528 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2005 | 73 | 0.020 |
Why?
|
| Dermis | 1 | 2007 | 207 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2006 | 537 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 5751 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 9386 | 0.020 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2005 | 138 | 0.020 |
Why?
|
| Mice, Nude | 1 | 1991 | 3689 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 1105 | 0.020 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2005 | 97 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 13284 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2005 | 190 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 286 | 0.010 |
Why?
|
| Amylases | 2 | 1994 | 173 | 0.010 |
Why?
|
| Liver Regeneration | 1 | 2005 | 210 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 15540 | 0.010 |
Why?
|
| Incidence | 2 | 2019 | 20947 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 669 | 0.010 |
Why?
|
| Prospective Studies | 4 | 2014 | 53288 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2011 | 2902 | 0.010 |
Why?
|
| Hepatitis | 1 | 2005 | 227 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 2 | 1994 | 191 | 0.010 |
Why?
|
| Medicare | 2 | 2016 | 6566 | 0.010 |
Why?
|
| Renal Circulation | 1 | 2003 | 333 | 0.010 |
Why?
|
| Genotype | 1 | 2017 | 12951 | 0.010 |
Why?
|
| Prevalence | 1 | 2019 | 15226 | 0.010 |
Why?
|
| Signal Transduction | 3 | 2012 | 23403 | 0.010 |
Why?
|
| Crystallization | 1 | 2003 | 524 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2000 | 5256 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 13695 | 0.010 |
Why?
|
| Cell Movement | 2 | 2006 | 5217 | 0.010 |
Why?
|
| Duodenum | 2 | 1995 | 483 | 0.010 |
Why?
|
| Heart | 1 | 1995 | 4467 | 0.010 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 57776 | 0.010 |
Why?
|
| Transplantation Conditioning | 2 | 1999 | 1598 | 0.010 |
Why?
|
| Materials Testing | 1 | 2005 | 867 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3920 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2003 | 458 | 0.010 |
Why?
|
| Young Adult | 2 | 2020 | 56430 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2007 | 1530 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2001 | 517 | 0.010 |
Why?
|
| Cardioplegic Solutions | 1 | 2000 | 118 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2014 | 3679 | 0.010 |
Why?
|
| Fat Necrosis | 1 | 2000 | 58 | 0.010 |
Why?
|
| HIV Infections | 1 | 2006 | 16718 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2000 | 84 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 733 | 0.010 |
Why?
|
| Episode of Care | 1 | 2000 | 126 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2007 | 2077 | 0.010 |
Why?
|
| Capillary Leak Syndrome | 1 | 1999 | 31 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 2000 | 332 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2005 | 1354 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 20822 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2010 | 4026 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2011 | 2987 | 0.010 |
Why?
|
| Algorithms | 1 | 2000 | 13881 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 3798 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 853 | 0.010 |
Why?
|
| Cattle | 1 | 2005 | 3922 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2007 | 3557 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 2002 | 646 | 0.010 |
Why?
|
| Rehabilitation Centers | 1 | 2000 | 254 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 697 | 0.010 |
Why?
|
| Gallbladder | 1 | 2000 | 302 | 0.010 |
Why?
|
| Chimera | 1 | 1999 | 485 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1999 | 433 | 0.010 |
Why?
|
| Infant | 3 | 1994 | 35136 | 0.010 |
Why?
|
| Prognosis | 2 | 2013 | 29063 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 6386 | 0.010 |
Why?
|
| Breast | 1 | 2007 | 1969 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2001 | 1147 | 0.010 |
Why?
|
| Lac Operon | 1 | 1997 | 238 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2282 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 1998 | 143 | 0.010 |
Why?
|
| C-Peptide | 1 | 1999 | 419 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 1998 | 263 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1999 | 684 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1998 | 520 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 1411 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2005 | 1486 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2001 | 1402 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1999 | 592 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 2088 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2001 | 1124 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2007 | 4161 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2005 | 1736 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2002 | 9146 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1997 | 718 | 0.010 |
Why?
|
| Probability | 1 | 2001 | 2505 | 0.010 |
Why?
|
| Factor VIII | 1 | 1998 | 347 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 2203 | 0.010 |
Why?
|
| Vena Cava, Superior | 1 | 1996 | 193 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 1998 | 579 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2001 | 1200 | 0.010 |
Why?
|
| Cell Count | 1 | 1999 | 1856 | 0.010 |
Why?
|
| Jugular Veins | 1 | 1996 | 204 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 4982 | 0.010 |
Why?
|
| Plasma | 1 | 1998 | 575 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1998 | 894 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1994 | 41006 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1995 | 588 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 1997 | 612 | 0.010 |
Why?
|
| Fibronectins | 1 | 1998 | 726 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2005 | 2585 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 4568 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1999 | 1880 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1994 | 378 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1998 | 662 | 0.010 |
Why?
|
| Syndrome | 1 | 2000 | 3251 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 1999 | 761 | 0.010 |
Why?
|
| Autoimmunity | 1 | 2002 | 1349 | 0.010 |
Why?
|
| Placebos | 1 | 1998 | 1676 | 0.010 |
Why?
|
| Fasting | 1 | 2000 | 1593 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1997 | 1079 | 0.010 |
Why?
|
| Anal Canal | 1 | 1996 | 376 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 2967 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1997 | 679 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1997 | 1100 | 0.010 |
Why?
|
| Perfusion | 1 | 1997 | 1360 | 0.010 |
Why?
|
| Hematuria | 1 | 1994 | 235 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 1679 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 15997 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 1821 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1998 | 1127 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 13033 | 0.010 |
Why?
|
| Constipation | 1 | 1996 | 546 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 1998 | 957 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1995 | 2031 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2003 | 2958 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10481 | 0.010 |
Why?
|
| Cyclosporins | 1 | 1991 | 220 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 1999 | 1373 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1998 | 3206 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8642 | 0.010 |
Why?
|
| Vaccination | 1 | 2001 | 3278 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1994 | 1842 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1999 | 3474 | 0.000 |
Why?
|
| Treatment Failure | 1 | 1994 | 2618 | 0.000 |
Why?
|
| Pancreas | 1 | 1995 | 1686 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1998 | 2508 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 2001 | 11031 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1997 | 2948 | 0.000 |
Why?
|
| Diabetic Nephropathies | 1 | 1994 | 984 | 0.000 |
Why?
|
| Stem Cells | 1 | 1999 | 3567 | 0.000 |
Why?
|
| Ischemia | 1 | 1995 | 1907 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1997 | 4217 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1995 | 1470 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 12959 | 0.000 |
Why?
|
| Contrast Media | 1 | 1995 | 5300 | 0.000 |
Why?
|
| Acute Disease | 1 | 1992 | 7149 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1995 | 14722 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 1994 | 19905 | 0.000 |
Why?
|